Pomerantz Appointed Co-Lead Counsel in Homology Medicines Securities Litigation

On July 1, 2022, U.S. District Judge Fernando L. Aenlle-Rocha of the Central District of California appointed Pomerantz LLP as Co-Lead Counsel on behalf of Jason Rofeh – the Co-Lead Plaintiff, and the class, in Pizzuto v. Homology Medicines, Inc., 22-cv-1968 (C.D. Cal.). This securities action alleges that Homology Medicines, Inc. misled the market regarding the efficacy of its lead product candidate, HMO-102 – a gene therapy for the treatment of phenylketonuria in adults – and overstated the regulatory and commercial prospects for the drug. Homology is a genetic medicines company that develops treatments for rare genetic diseases at…